159 related articles for article (PubMed ID: 37478874)
41. Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers Bias.
Pai MP; Hong J; Krop L
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096158
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic Drug Monitoring Coupled With Bayesian Forecasting Could Prevent Vancomycin-Associated Nephrotoxicity in Renal Insufficiency Patients: A Prospective Study and Pharmacoeconomic Analysis.
Zhang Y; Wang T; Zhang D; You H; Dong Y; Liu Y; Du Q; Sun D; Zhang T; Dong Y
Ther Drug Monit; 2020 Aug; 42(4):600-609. PubMed ID: 32097248
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels.
Haeseker M; Croes S; Neef C; Bruggeman C; Stolk L; Verbon A
Ther Drug Monit; 2016 Feb; 38(1):120-6. PubMed ID: 26418699
[TBL] [Abstract][Full Text] [Related]
45. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
46. Comparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients.
Denaro CP; Ravenscroft PJ
Br J Clin Pharmacol; 1989 Jul; 28(1):37-44. PubMed ID: 2775614
[TBL] [Abstract][Full Text] [Related]
47. Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Clinical Study in Elderly Patients.
Bel Kamel A; Bourguignon L; Marcos M; Ducher M; Goutelle S
Ther Drug Monit; 2017 Feb; 39(1):83-87. PubMed ID: 27861313
[TBL] [Abstract][Full Text] [Related]
48. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
Pai MP; Neely M; Rodvold KA; Lodise TP
Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
[TBL] [Abstract][Full Text] [Related]
49. Estimation of population pharmacokinetics using the Gibbs sampler.
Best NG; Tan KK; Gilks WR; Spiegelhalter DJ
J Pharmacokinet Biopharm; 1995 Aug; 23(4):407-35. PubMed ID: 8882748
[TBL] [Abstract][Full Text] [Related]
50. Predictive performance of gentamicin dosing nomograms.
Lee J; Yoon S; Shin D; Han H; An H; Lee J; Lim KS; Yu KS; Lee H
Drug Des Devel Ther; 2014; 8():1097-106. PubMed ID: 25152616
[TBL] [Abstract][Full Text] [Related]
51. Vancomycin therapeutics and monitoring: a contemporary approach.
Avent ML; Vaska VL; Rogers BA; Cheng AC; van Hal SJ; Holmes NE; Howden BP; Paterson DL
Intern Med J; 2013 Feb; 43(2):110-9. PubMed ID: 23185970
[TBL] [Abstract][Full Text] [Related]
52. Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug.
Uematsu T
Int J Clin Pharmacol Ther Toxicol; 1993 Dec; 31(12):606-10. PubMed ID: 8314363
[TBL] [Abstract][Full Text] [Related]
53. The characteristics and impact indicator of vancomycin pharmacokinetics in cancer patients complicated with severe pneumonia.
Zhang X; Wang D
J Infect Chemother; 2020 May; 26(5):492-497. PubMed ID: 31983615
[TBL] [Abstract][Full Text] [Related]
54. Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients.
Turner RB; Kojiro K; Shephard EA; Won R; Chang E; Chan D; Elbarbry F
Pharmacotherapy; 2018 Dec; 38(12):1174-1183. PubMed ID: 30362592
[TBL] [Abstract][Full Text] [Related]
55. Vancomycin monitoring: one or two serum levels?
Andrés I; López R; Pou L; Piñol F; Pascual C
Ther Drug Monit; 1997 Dec; 19(6):614-9. PubMed ID: 9421100
[TBL] [Abstract][Full Text] [Related]
56. Bayesian pharmacokinetics of gentamicin in a haemodialysis population.
Vercaigne LM; Ariano RE; Zacharias JM
Clin Pharmacokinet; 2004; 43(3):205-10. PubMed ID: 14871157
[TBL] [Abstract][Full Text] [Related]
57. Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin.
Lee BV; Fong G; Bolaris M; Neely M; Minejima E; Kang A; Lee G; Gong CL
Clin Microbiol Infect; 2021 Sep; 27(9):1346.e1-1346.e7. PubMed ID: 33221430
[TBL] [Abstract][Full Text] [Related]
58. Bayesian forecasting of aminoglycoside dosing requirements in obese patients: influence of subpopulation versus general population pharmacokinetic parameters as the internal estimates.
McClellan SD; Farringer JA
Ther Drug Monit; 1989; 11(4):431-6. PubMed ID: 2741192
[TBL] [Abstract][Full Text] [Related]
59. The influence of assay error weight on gentamicin pharmacokinetics using the Bayesian and nonlinear least square regression analysis in appendicitis patients.
Burm JP
Arch Pharm Res; 2005 May; 28(5):598-603. PubMed ID: 15974449
[TBL] [Abstract][Full Text] [Related]
60. Predictive Performance of Bayesian Vancomycin Monitoring in the Critically Ill.
Narayan SW; Thoma Y; Drennan PG; Yejin Kim H; Alffenaar JW; Van Hal S; Patanwala AE
Crit Care Med; 2021 Oct; 49(10):e952-e960. PubMed ID: 33938713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
